Net costs, net QALYs gained, and cost per QALY gained as compared to no treatment programme for the 30% and 45% HCV prevalence scenarios and various optimisation programmes.

The optimal 10 year programme is determined for each scenario, and then costs and QALYs are calculated for a further 40 years (for a 50 year time horizon) in order to account for the onward prevention benefits of the treatment programme. Scenario A: minimising health service costs and HCV health utility losses (measured in monetarised QALY loss). Scenario B: minimising health service costs and HCV health utility losses with a final time prevalence target. Scenario C: minimising only health service costs with a final time prevalence target.1Net costs = health care costs over 50 years with the 10 year treatment programme - health care costs over 50 years with no treatment. Health care costs are defined as programme (antiviral treatment and search) costs as well as HCV infection related costs.2Net QALY gain = QALYs gained over 50 years with the 10 year treatment programme - QALYs gained over 50 years with no treatment.